Press Release

HOLLISTON, Mass.--(BUSINESS WIRE)--Feb. 19, 2007--Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce results for the fourth quarter and year ended December 31, 2006 after market trading hours on Thursday, March 1, 2007.

At 5:30 p.m. Eastern Time on Thursday, March 1, 2007, management will host a conference call to discuss the Company's quarterly results. In addition, management may answer questions concerning business and financial developments and trends, the Company's view on earnings forecasts, and other business and financial matters affecting the Company. Some of the information to be presented on the call or provided in response to questions may contain information that has not previously been disclosed.

The conference call will be simultaneously broadcast over the Internet and can be accessed through the Harvard Bioscience, Inc. website. To listen to the conference call, log on to our website at www.harvardbioscience.com and click on the Earnings Call icon. Financial and other statistical information presented on the call, including our earnings release, will also be available on the investor relations section of our website. Click on the investor relations' button and then click on the press release or web cast icon, as appropriate. If you are unable to listen to the live web cast, the call will be archived in the investor relations section of our web site. The live conference call can also be accessed by dialing 800-561-2601 and referencing the pass code of "89328221".

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer, and marketer of a broad range of specialized products, primarily scientific instruments and apparatus, used to improve life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. HBIO sells its products to thousands of researchers in over 100 countries through its direct sales force, its 1,100 page catalog (and various other specialty catalogs), its website and through its distributors, including GE Healthcare, Fisher Scientific and VWR. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, and Austria with additional facilities in France and Canada. For more information, please visit www.harvardbioscience.com.

The statements made in this press release that are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements include, but are not limited to, those factors set forth under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005 or described in the Company's other public filings. The Company's results may also be affected by factors of which the Company is not currently aware. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.

    CONTACT: Harvard Bioscience, Inc.
             David Green, President
             dgreen@harvardbioscience.com
             or
             Chane Graziano, CEO
             cgraziano@harvardbioscience.com
             or
             Bryce Chicoyne, CFO
             bchicoyne@harvardbioscience.com
             Tel: 508-893-8999
             Fax: 508-429-8478

    SOURCE: Harvard Bioscience, Inc.

Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.